 | • レポートコード：MRC23Q37248 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のエプタコグアルファ（rFVIIa）市場について調査・分析し、世界のエプタコグアルファ（rFVIIa）市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（凍結乾燥製剤、凍結乾燥粉体）、用途別セグメント分析（血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT））、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Novo Nordisk、LFB SA、GENERIUM、Northland-bio、CSL、Shire (Takeda)、Bayerなどが含まれています。 世界のエプタコグアルファ（rFVIIa）市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、エプタコグアルファ（rFVIIa）市場規模を推定する際に考慮しました。本レポートは、エプタコグアルファ（rFVIIa）の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、エプタコグアルファ（rFVIIa）に関するビジネス上の意思決定に役立てることを目的としています。 ・エプタコグアルファ（rFVIIa）市場の概要 - 製品の定義 - エプタコグアルファ（rFVIIa）のタイプ別セグメント - 世界のエプタコグアルファ（rFVIIa）市場規模：タイプ別分析（凍結乾燥製剤、凍結乾燥粉体） - エプタコグアルファ（rFVIIa）の用途別セグメント - 世界のエプタコグアルファ（rFVIIa）市場規模：用途別分析（血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT）） - 世界のエプタコグアルファ（rFVIIa）市場規模予測（2018年-2029年） - エプタコグアルファ（rFVIIa）の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - エプタコグアルファ（rFVIIa）市場の競争状況およびトレンド ・エプタコグアルファ（rFVIIa）の地域別市場規模 - 北米のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - アメリカのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - ヨーロッパのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - アジア太平洋のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - 中国のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - 日本のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - 韓国のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - インドのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - オーストラリアのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - 中南米のエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） - 中東・アフリカのエプタコグアルファ（rFVIIa）市場規模（2018年-2029年） ・タイプ別セグメント：凍結乾燥製剤、凍結乾燥粉体 - 世界のエプタコグアルファ（rFVIIa）のタイプ別販売量（2018年-2023年） - 世界のエプタコグアルファ（rFVIIa）のタイプ別売上（2018年-2023年） - 世界のエプタコグアルファ（rFVIIa）のタイプ別価格 ・用途別セグメント：血友病、後天性血友病、第VII因子欠乏症、グランツマン血栓症（GT） - 世界のエプタコグアルファ（rFVIIa）の用途別販売量（2018年-2023年） - 世界のエプタコグアルファ（rFVIIa）の用途別売上（2018年-2023年） - 世界のエプタコグアルファ（rFVIIa）の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Novo Nordisk、LFB SA、GENERIUM、Northland-bio、CSL、Shire (Takeda)、Bayer ・産業チェーンと販売チャネルの分析 - エプタコグアルファ（rFVIIa）産業チェーン分析 - エプタコグアルファ（rFVIIa）の主要原材料 - エプタコグアルファ（rFVIIa）の販売チャネル - エプタコグアルファ（rFVIIa）のディストリビューター - エプタコグアルファ（rFVIIa）の主要顧客 ・エプタコグアルファ（rFVIIa）市場ダイナミクス - エプタコグアルファ（rFVIIa）の業界動向 - エプタコグアルファ（rFVIIa）市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Highlights
The global Eptacog Alfa (rFVIIa) market was valued at US$ 1190 million in 2022 and is anticipated to reach US$ 1654.2 million by 2029, witnessing a CAGR of 4.6% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa).
The Eptacog Alfa (rFVIIa) market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Eptacog Alfa (rFVIIa) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eptacog Alfa (rFVIIa) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Eptacog Alfa (rFVIIa) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eptacog Alfa (rFVIIa) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Eptacog Alfa (rFVIIa) and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Eptacog Alfa (rFVIIa) industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eptacog Alfa (rFVIIa).
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
1 Eptacog Alfa (rFVIIa) Market Overview
1.1 Product Overview and Scope of Eptacog Alfa (rFVIIa)
1.2 Eptacog Alfa (rFVIIa) Segment by Type
1.2.1 Global Eptacog Alfa (rFVIIa) Market Value Comparison by Type (2023-2029)
1.2.2 Freeze-dried Preparation
1.2.3 Freeze-dried Powder
1.3 Eptacog Alfa (rFVIIa) Segment by Application
1.3.1 Global Eptacog Alfa (rFVIIa) Market Value by Application: (2023-2029)
1.3.2 Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Factor VII Deficiency
1.3.5 Glanzmann Thrombasthenia (GT)
1.4 Global Eptacog Alfa (rFVIIa) Market Size Estimates and Forecasts
1.4.1 Global Eptacog Alfa (rFVIIa) Revenue 2018-2029
1.4.2 Global Eptacog Alfa (rFVIIa) Sales 2018-2029
1.4.3 Global Eptacog Alfa (rFVIIa) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Eptacog Alfa (rFVIIa) Market Competition by Manufacturers
2.1 Global Eptacog Alfa (rFVIIa) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturers (2018-2023)
2.4 Global Eptacog Alfa (rFVIIa) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Product Type & Application
2.7 Eptacog Alfa (rFVIIa) Market Competitive Situation and Trends
2.7.1 Eptacog Alfa (rFVIIa) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eptacog Alfa (rFVIIa) Players Market Share by Revenue
2.7.3 Global Eptacog Alfa (rFVIIa) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eptacog Alfa (rFVIIa) Retrospective Market Scenario by Region
3.1 Global Eptacog Alfa (rFVIIa) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Sales by Region: 2018-2029
3.2.1 Global Eptacog Alfa (rFVIIa) Sales by Region: 2018-2023
3.2.2 Global Eptacog Alfa (rFVIIa) Sales by Region: 2024-2029
3.3 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Revenue by Region: 2018-2029
3.3.1 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2018-2023
3.3.2 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2024-2029
3.4 North America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.4.1 North America Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.4.3 North America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.5.1 Europe Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.5.3 Europe Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.6.1 Asia Pacific Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.6.3 Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.7.1 Latin America Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.7.3 Latin America Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.8.1 Middle East and Africa Eptacog Alfa (rFVIIa) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Eptacog Alfa (rFVIIa) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Eptacog Alfa (rFVIIa) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2018-2029)
4.1.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2018-2023)
4.1.2 Global Eptacog Alfa (rFVIIa) Sales by Type (2024-2029)
4.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Type (2018-2029)
4.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2018-2029)
4.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Type (2018-2023)
4.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2024-2029)
4.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Type (2018-2029)
4.3 Global Eptacog Alfa (rFVIIa) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2018-2029)
5.1.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2018-2023)
5.1.2 Global Eptacog Alfa (rFVIIa) Sales by Application (2024-2029)
5.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Application (2018-2029)
5.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2018-2029)
5.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Application (2018-2023)
5.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2024-2029)
5.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Application (2018-2029)
5.3 Global Eptacog Alfa (rFVIIa) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA
6.2.1 LFB SA Corporation Information
6.2.2 LFB SA Description and Business Overview
6.2.3 LFB SA Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 LFB SA Eptacog Alfa (rFVIIa) Product Portfolio
6.2.5 LFB SA Recent Developments/Updates
6.3 GENERIUM
6.3.1 GENERIUM Corporation Information
6.3.2 GENERIUM Description and Business Overview
6.3.3 GENERIUM Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GENERIUM Eptacog Alfa (rFVIIa) Product Portfolio
6.3.5 GENERIUM Recent Developments/Updates
6.4 Northland-bio
6.4.1 Northland-bio Corporation Information
6.4.2 Northland-bio Description and Business Overview
6.4.3 Northland-bio Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Northland-bio Eptacog Alfa (rFVIIa) Product Portfolio
6.4.5 Northland-bio Recent Developments/Updates
6.5 CSL
6.5.1 CSL Corporation Information
6.5.2 CSL Description and Business Overview
6.5.3 CSL Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CSL Eptacog Alfa (rFVIIa) Product Portfolio
6.5.5 CSL Recent Developments/Updates
6.6 Shire (Takeda)
6.6.1 Shire (Takeda) Corporation Information
6.6.2 Shire (Takeda) Description and Business Overview
6.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Product Portfolio
6.6.5 Shire (Takeda) Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer Eptacog Alfa (rFVIIa) Product Portfolio
6.7.5 Bayer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eptacog Alfa (rFVIIa) Industry Chain Analysis
7.2 Eptacog Alfa (rFVIIa) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eptacog Alfa (rFVIIa) Production Mode & Process
7.4 Eptacog Alfa (rFVIIa) Sales and Marketing
7.4.1 Eptacog Alfa (rFVIIa) Sales Channels
7.4.2 Eptacog Alfa (rFVIIa) Distributors
7.5 Eptacog Alfa (rFVIIa) Customers
8 Eptacog Alfa (rFVIIa) Market Dynamics
8.1 Eptacog Alfa (rFVIIa) Industry Trends
8.2 Eptacog Alfa (rFVIIa) Market Drivers
8.3 Eptacog Alfa (rFVIIa) Market Challenges
8.4 Eptacog Alfa (rFVIIa) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer